This Government Contract opportunity was posted on May 3, 2011. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Purchase of High Performance Liquid Chromatography GeneSys Newborn Screening Analyzer

Awarded

94994Federal

Submission Closed05/03/2011, 12:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413

New

Federal

Blood Type IVD Reagents and Sera SupplyThis subcontract involves the supply of Blood Type IVD Reagents and Sera to prime contractors supporting Department of Veterans Affairs VISN 22 medical supply contracts. The scope of work includes the manufacture or distribution of ABO reverse typing cells, antibody screening cells, and antibody identification cells, as well as the provision of Lewis Blood Group Substance and full antigen profiles. All delivered reagents must be FDA compliant and accompanied by Certificates of Analysis or Conformance. The contract is managed by the Network Contract Office 22 under NAICS code 325413, with a response deadline set for November 16, 2026.

262-NETWORK Contract Office 22 (36C262)

POSTED

DEADLINE

6550--Blood Type IVD Reagents

Solicitation # 36C26227Q0043

The Department of Veterans Affairs, through the Network Contract Office 22, is seeking quotations for solicitation 36C26227Q0043 to establish a Blanket Purchase Agreement for blood type IVD reagents, supplies, and consumables for manual testing at VISN 22 facilities. The contract is structured with a 12-month base ordering period and four subsequent 12-month option periods, for a total potential duration of five years. This is a commercial products and services acquisition under FAR Part 12, with an emphasis on FDA regulatory compliance, potency requirements, and strict cold-chain and temperature-monitoring controls during shipment. All items must be quoted as F.O.B. destination and delivered Monday through Friday between 8am and 4pm. Award will be based on the best value to the government, evaluated through a comparative assessment of technical understanding, price, and quality, regulatory compliance, and product traceability. Technical evaluation considers the offeror's ability to provide a full antigen profile and their procedures for handling nonconforming or defective products. Pricing will be evaluated based on the total cost for the base period and all option periods, including a six-month price addition for the final performance period per FAR 52.217-8. Quotations must be submitted via email to the contract specialist by November 16, 2026, and must include a completed five-year pricing spreadsheet, a past performance questionnaire, and required certifications regarding telecommunications and trade agreements.

262-NETWORK Contract Office 22 (36C262)

POSTED

DEADLINE

Reagents and consumables for Roche immunostainers

Solicitation # 75N98027Q00026

National Institutes Of Health Olao

POSTED

DEADLINE

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-27-T-1071

Solicitation SPE2DS-27-T-1071, issued by the DLA Troop Support Medical Supply Chain, is for the procurement of one case of Abbott BinaxNOW COVID-19 Antigen self-test kits for over-the-counter, at-home use. Each case contains 12 kits with 2 tests per kit. The items must be stored between 2-30 degrees Celsius and have a non-extendable shelf life of 12 months, with no more than one month elapsed from the date of manufacture to the date of delivery. Delivery is required within 20 days after receipt of the order, with a final delivery date of October 30, 2026, to the USS IDAHO (SSN 799). The contract mandates strict adherence to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and requires labels to include the contract or lot number and the date of manufacture, expiration, or retest. Packaging must be commercial, utilizing sealed unit containers and suitable exterior shipping containers. Inspection and acceptance will occur at the destination per FAR 52.246-2. Administrative requirements include the use of the Wide Area Workflow system for electronic invoicing and compliance with various FAR and DFARS clauses regarding cybersecurity, the Buy American Act, and the prohibition of covered defense telecommunications equipment. Quotations are due by November 3, 2026.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CULTURE MEDIUM, THAYER-

Solicitation # SPE2DS-27-T-1066

Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supply of ALBAcyte Blood Bank ReagentsThis subcontract involves the manufacture and supply of specialized ALBAcyte blood bank reagents for prime contractors supporting the Department of Veterans Affairs North Texas Health Care System. The scope of work includes the delivery of A1, A2, B, IgG Sensitized, Antibody ID Panels, and C3 Coated RBCs. To ensure product efficacy, the contractor must utilize shipping containers that maintain reagent integrity and adhere to a defined Quality Plan and FDA approval standards. Deliveries are to be made FOB Destination to the Transfusion Medicine Unit located in Dallas, Texas. The contract is categorized under NAICS code 325413 and is managed through the Department of Veterans Affairs Network Contract Office 17.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

6550--Blood Bank Reagents

Solicitation # 36C25727Q0065

The Department of Veterans Affairs VA North Texas Health Care System is issuing a Sources Sought Notice to identify qualified vendors capable of providing blood bank reagents for the Transfusion Medicine Unit in Dallas, Texas. These reagents, including ALBAcyte A1, A2, B, IgG Sensitized, Antibody ID Panels, and C3 Coated Red Blood Cells, are essential for manual blood typing and serum antibody detection used in cross-matching blood for transfusions. The anticipated acquisition strategy includes a base year starting May 1, 2027, with four subsequent one-year option periods extending through April 30, 2032. To be considered, vendors must be FDA approved, provide documentation of such approval, and maintain a defined quality plan with adequate supply availability. All shipments must be FOB Destination, and the contractor is responsible for providing appropriate shipping containers. Interested vendors must submit an electronic capability statement in PDF or Word format, including the place of manufacture for all listed reagents, to the designated contract specialist by November 5, 2026, at 9:00 AM CST. This notice is for market research purposes only to determine the appropriate acquisition strategy, such as a small business set-aside, and does not constitute a formal solicitation.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

6505--DRESSING, DRAWTEX 4IN X 4IN (VA-27-00014447)

Solicitation # 36C77027Q0015

The Department of Veterans Affairs, National CMOP Office, is conducting market research through a Sources Sought announcement to identify qualified sources for the procurement of Drawtex Dressing, 4in X 4in, packaged as 10ct per box. This action is for market research purposes only and is not a formal solicitation for quotes; therefore, no contract will be awarded based on this specific announcement. The place of performance is located in Ladson, South Carolina, and the primary point of contact is Contract Specialist Claudine Challinor. Interested respondents must submit their information via email by November 3, 2026. Required details include the company's SAM Unique ID Number, business size (Small, Large, SDVOSB, or VOSB), and point of contact information. Specifically, the government is seeking to determine if the respondent is the manufacturer, the manufacturer's product number, and the place of manufacturing. If the respondent is not the manufacturer, they must provide a letter of authorization from the original equipment manufacturer or provide detailed product literature and specifications for alternative products that demonstrate similarities to the Drawtex hydro conductive wound dressing.

National Cmop Office (36C770)

POSTED

DEADLINE

6550--Optilite analyzer reagents

Solicitation # 36C26227Q0052

The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.

262-NETWORK Contract Office 22 (36C262)

POSTED

DEADLINE

Supply of i-STAT PT Plus Control Reagent Level 1This subcontract involves the procurement and delivery of i-STAT PT Plus Control Reagent Level 1 for coagulation testing to support prime contractors fulfilling Department of Defense supply contracts. The scope of work requires the delivery of two boxes, each containing ten 1.0 mL units, shipped FOB Destination to a performance location in APO 96260-5479. To ensure quality and safety, all supplied reagents must adhere to Regulation 864.7750 Class II requirements and maintain full compliance with Registration, Listing, Labeling, and Good Manufacturing Practices. This requirement is managed under NAICS code 325413 for the Medical Supply Chain MD Surg FSF agency.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL SET, BLOOD CHEM

Solicitation # SPE2DS-27-T-0906

Solicitation SPE2DS-27-T-0906 is a request for quotations from DLA Troop Support for two sets of DXH 500 Series Blood Chemistry Control (NSN 6550-01-688-9090). This assayed whole blood control is used to monitor multi-parameter hematology cell counters and includes abnormal low, normal, and abnormal high components. The items must be stored refrigerated and upright between 2 to 8 degrees Celsius and protected from freezing and overheating. Delivery is required within 20 days after receipt of order, with a required delivery date of October 27, 2026, under FOB Destination terms. The contract imposes strict shelf-life requirements, specifying a non-extendable shelf life of 3 months, with no more than 13 days elapsed from the date of manufacture to the date of delivery. Packaging must be commercial and compliant with RP001 and MIL-STD-2073-1E, while marking must adhere to Medical Marking Standard No. 1. Invoicing is to be processed electronically via the Wide Area Workflow system. This is not a small business set-aside, and the procurement falls under NAICS code 325413. Compliance with the Buy American and Balance of Payments Program and DFARS safeguarding of covered defense information is required.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, BLOOD CHEMISTR

Solicitation # SPE2DS-27-T-0950

Solicitation SPE2DS-27-T-0950 is a Request for Quotations issued by the Department of Defense, DLA Troop Support Medical Supply Chain, for the procurement of two boxes of i-STAT PT Plus Control Reagent Level 1 (NSN 6550-01-728-5703). This reagent is used for coagulation testing and is compatible with the i-STAT PT Plus cartridge and the i-STAT 1 Government Field Kit analyzer. Each box contains ten 1.0 mL units. The required delivery date is October 23, 2026, with a delivery window of 83 days after award. Inspection and acceptance will occur at the destination per FAR 52.246-2. The contract mandates strict quality and storage requirements, including refrigeration between 2 to 8 degrees Celsius and a non-extendable shelf life of 12 months. Items must be delivered within one month of the manufacture date. Packaging must be commercial and adhere to MIL-STD-2073-1E and RP001, with marking compliant with Medical Marking Standard No. 1. Labels must include the contract/lot number and manufacture or expiration dates. The procurement is not a small business set-aside, though a HUBZone price evaluation preference may be applied. Compliance with the Buy American Act and DFARS domestic material restrictions is required, and electronic invoicing must be processed through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

5 days ago

DEADLINE

in 3 days

AI Contract Overview

The Centers for Disease Control and Prevention intends to award a sole source contract to Trinity Biotech USA, Inc. for the acquisition of a High Performance Liquid Chromatography GeneSYS Newborn Screening Analyzer. This procurement, falling under NAICS code 325412, has a performance period of five months. The agency has identified Trinity Biotech as the only responsible source capable of meeting its specific technical requirements, particularly the need for an instrument that can perform both quick screening and high-resolution confirmatory runs using the same reagents and columns. The GeneSYS analyzer is essential for the Newborn Screening Molecular Biology Branch to identify thalassemisa and various hemoglobin variants, including A, S, C, D, E, O, and Bart's. Key technical capabilities include automated hemolysate preparation, a Windows XP-based customizable software system, and the ability to automatically reflex from a two-minute Quick Scan to an eight-minute High Resolution program for unattended operation. This system was selected over other options due to its superior flexibility, automated identification capabilities, and ability to maintain continuity of current laboratory methods.

General Info

Agency

N/A

Contract Value

$58,145

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

CDC Facility, USA

Set-Aside

NONE

Awardee

Biopool/Trinity Biotech, Inc. 2823 Girts Road JAMESTOWN NY 14701-9666 USA

Award Issued Date

05/03/2011, 12:00:00 AM UTC

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded

PostedApr 12

Presolicitation

AwardedMay 3

Contract was awarded

Submission Closed

05/03/2011, 12:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyN/A

Contacts1 person available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

Contacts

Vallerie M ReddContracting Officer

contact@example.gov

+1 (555) 000-0000

Full Description

The Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH), Division of Laboratory Sciences, intends to award a sole source contract to Trinity Biotech USA, Inc., 2823 Girts Road, Jamestown, NY 14701 for the acquisition of a High Performance Liquid Chromatography GeneSYS Newborn Screening Analyzer. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 325412, Pharmaceutical Preparation Manufacturing. The period of performance for this procurement is 5 months. The Trinity Biotech High Performance Liquid Chromatography GeneSys Newborn Screening Analyzer can provide both a screening run and a confirmatory run as well as identify thalassemisa in addition to hemoglobin variants. This instrument will also allow CDC continuity of the current methods run in our laboratory and it will fulfill all of our requirements by performing all of the following functions. - The hemoglobin fractionation system employs the principles of ion-exchange chromatography and high performance liquid chromatography. - The system utilizes a Windows XPTM based program especially designed for hemoglobin variant analysis of neonatal samples. - The software is able to be changed/customized at any time to accommodate laboratory needs. - The system incorporates a 2 minute Quick Scan program and an 8 minute High Resolution program with the ability to automatically reflex from Quick Scan program to High Resolution program for unattended screening and confirmation of hemoglobin variants in neonatal and adult (samples not considered neonatal) samples. - System is able to perform screening-2minute and confirmation-8 minute testing utilizing the same reagents and columns. - Reagents and columns are not lot dependant. User will be able to use any combination of lot reagents with any lot columns. - The system uses a FASC reference material - The system uses a relative retention time approach in the presumptive identification of variant hemoglobin. - The system offers automated hemolysate preparation for dried blood spots in a microtiter plate and direct sampling of microtiter plates. The automated sample preparation is an integrated step in the sampling program selected by user. - The system produces reports with the sample identification information, date and time, followed by the chromatogram with retention times indicated at the apex of each peak. A peak summary report can be printed after the chromatogram with the retention time, relative retention time, % area, phenotype and comments for each peak in the chromatogram. A batch summary report can be generated at the end of every run. - System is able to label Hbs; A, S, C, D, E, O and Bart's with presumptive IDs in the High Resolution mode. The phenotype for each sample is labeled based on the highest to lowest concentration of Hb. - Reports and results are able to be printed to a pdf file on the system or printed on 8" x 11" paper. This instrument is essential to the laboratory work of the Newborn Screening Molecular Biology Branch. As such, it is in continuous use and must be maintained appropriately to ensure accuracy and quality results. This is also the only vendor that can run both a 2 mintue Quick Scan program and an 8 minute High Resolution program using the same reagents and consumables. Furthermore, this is the only instrument that can automatically reflex from the Quick Scan to the High Resolution program for unattended screening and confirmation of hemoglobin variants. This is also the only instrument that is capable of identifying the of hemoglobinopathies A, S, C, D, E, O and Bart's with presumptive IDs in the High Resolution mode. The phenotype for each sample shall be labeled based on the highest to lowest concentration of Hb. This is also the only instrument that will allow our laboratory the flexibility to change and customize the software to accommodate other laboratory needs without purchasing a new instrument. Only Trinity Biotech and Bio-Rad Clinical Diagnostics have HPLC instruments and software specific for newborn screening specimens in the dried-blood spot matrix. We currently have a Bio-Rad instrument but it is less flexible, cannot confirm hemoglobin variants in a longer sampling time, and cannot identify thalassemia automatically. Other kits and columns would be required and it would be inefficient to switch between methods with one instrument. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Trinity Biotech. However, all responsible sources that believe they can meet these requirements may submit their capabilities/qualifications statement to provide the services to Vallerie Redd via email ONLY at contact@example.gov with the solicitation number 94994 referenced in the subject line NO LATER THAN April 27, 2011. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.